Despite two capital injections worth US$1bn and a return to net profit, Fubon's credit ratings remain under scrutiny due to money owed from reinsurance counterparties.
AM Best has assessed that the South Korean insurer's robust capitalisation plus the implementation of IFRS 17 should allay worries about valuation losses in its securities.